Amarin Corp plc (AMRN) Misses Q3 EPS by 4c
Tweet
Share
E-mailGet Alerts AMRN Hot Sheet
Price: $0.88 +1.15%
Revenue Growth %: -33.4%
Financial Fact:
Net and comprehensive loss: -15.77M
Today's EPS Names:
SFST, VLTO, CLIR, More
Revenue Growth %: -33.4%
Financial Fact:
Net and comprehensive loss: -15.77M
Today's EPS Names:
SFST, VLTO, CLIR, More
Join SI Premium – FREE
Amarin Corp plc (NASDAQ: AMRN) reported Q3 EPS of ($0.17), $0.04 worse than the analyst estimate of ($0.13).
Recognized $14.1 million in product revenue from Vascepa® (icosapent ethyl) sales in Q3 2014 compared to $12.6 million in Q2 2014 and $8.4 million in Q3 2013, an increase of 12% and 68%, respectively
For earnings history and earnings-related data on Amarin Corp plc (AMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Eastgroup Properties (EGP) Tops Q1 EPS by 17c, provides guidance
- KKR Real Estate Finance Trust (KREF) Tops Q1 EPS by 4c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
